Abivax S.A. (ABVX) saw its shares plummet 5.07% in pre-market trading on Tuesday, following the company's announcement of a widening third-quarter loss.
The biopharmaceutical company reported a Q3 loss of 2.10 euros per diluted share, significantly higher than the 0.87 euro loss recorded a year earlier. Despite a rise in operating income to 2 million euros from 1.3 million euros, the increased losses appear to have unsettled investors.
Abivax noted that it has sufficient cash reserves to fund operations through Q4 2027, but this assurance did not prevent the pre-market sell-off.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments